Drug Profile


Alternative Names: 430C78; BW 430C; Labileno; Lamactil; Lamictal; Lamictin

Latest Information Update: 01 Jun 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Antiepileptic drugs; Small molecules; Triazines
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bipolar disorders; Lennox-Gastaut syndrome; Partial epilepsies; Tonic-clonic epilepsy
  • Phase III Absence epilepsy; Epilepsy
  • Discontinued Diabetic neuropathies; Neuropathic pain; Schizophrenia

Most Recent Events

  • 16 May 2017 GlaxoSmithKline terminates a clinical trial in Bipolar disorders (Adjunctive treatment, In adolescents) in USA (NCT00284791)
  • 14 Jun 2016 Biomarkers information updated
  • 01 Nov 2015 GlaxoSmithKline completes a phase III trial in Absence epilepsy (In adolescents, In children, Monotherapy, Newly diagnosed) in Japan and South Korea (NCT01431976)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top